Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

Abstract

complete remission-1/25 (4%), partial remission-7/25 (28%), stable disease-6/25 (24%), and progressive disease-11/25 (44%), for an overall response rate of 8/25 (32%). Median duration of response was 6 months. Toxicities included hand-foot syndrome, mucositis, diarrhea, and nausea and vomiting, and required treatment interruption and/or dose attenuation in 9/25 patients (36%). No myelosuppression or serious catheter-related problems were seen. We conclude that continuous 5 FU infusion is a potentially effective salvage treatment that may provide meaningful palliation in some patients with carcinoma of the breast, in spite of extensive previous treatment.

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen

“…In an overview of six phase II studies involving 182 patients with refractory breast cancer, most of whom were pretreated with bolus 5-FU, an average response rate of 29% (range 17-53%) has been reported (Hansen, 1991). As originally suggested in the phase I study by Lokich and subsequently confirmed by phase II studies, myelosuppression, an important toxic effect occurring with bolus administration, is rarely reported with infusional 5-FU and the dose-limiting toxicities are stomatitis, diarrhoea and plantar-palmar erythema (Lokich et al, 1981;Hansen et al, 1987;Huan et al, 1989).…”

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer

“…Several studies have suggested independent improvements in the therapeutic index of both 5-FU in breast (Hansen et al, 1987;Gordon et al, 1990) and colonic (Lokich et al, 1989) cancer; and of anthracyclines in breast cancer (Gordon et al, 1990) and non-small-cell lung cancer (Valdivieso et al, 1984) using frequent low-dose scheduling. Other studies in breast cancer have shown equal efficacy and toxicity of low dose weekly anthracyclines compared with the three weekly regimens but demonstrated worsened quality of life for the weekly regimen (Twelves et al, 1991;Richards et al, 1992).…”

“…There has been interest recently in scheduling alterations of these agents in an attempt to produce improved response rates and increased dose AUCs while minimising acute toxicities, i.e. attempting to enhance the therapeutic index of these agents (Hansen et al, 1987;Twelves et al, 1991).…”

Efectividad de 5-fluoruracilo y vinorelbina en pacientes multitratadas por cáncer de mama metastásico

“…Varios estudios han demostrado que el 5FU administrado en IC a dosis >450 mg/m 2 superficie corporal (SC) conducen a índices de respuesta superiores al 53% en primera línea de tratamiento 17,18 . En segunda línea, los índices de respuesta son de un ~30% [19][20][21][22] . El 5FU cuando se administra en IC es menos mielotóxi-co, lo que permite combinarlo con otros fármacos como la vinorelbina.…”